focus -WSS

focus

author：Wikipedia 2025-09-14 14:46:19 - browse：93463

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： A strong 6.5

WSS

First recipient of genetically engineered pig kidney has died

Researchers on aging grapple with how to calculate biological age

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Google says AlphaFold 3 can map a vast universe of biomolecules

Study: Hearing aids may slow cognitive decline in those at risk

Study: Adult vaccinations pay for themselves in societal benefits

hotspot

focus

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Twill hunts for pharma partner to market its depression app

Malaria cases in Florida and Texas: Here’s what you need to know

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

BioMarin wins approval for gene therapy to treat hemophilia A

H5N1 bird flu: what we're starting to learn about infection in cows

Trump demands the U.S. pay no more for drugs than other countries … again

BridgeBio heart drug succeeds in pivotal study

What does generative AI mean for health care? We asked experts

Telehealth startups turn to complex chronic diseases

focus

Study: Hearing aids may slow cognitive decline in those at risk

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

UK homeowners get some respite as inflation falls by more than anticipated to a 15

US soldier in North Korean custody after crossing DMZ line

Software glitch causes Tandem insulin pump to shutdown, FDA warns

H5N1 bird flu: what we're starting to learn about infection in cows

leisure time

explore

focus

leisure time